You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
AstraZeneca
Medtronic
McKinsey
McKesson

Last Updated: April 8, 2020

DrugPatentWatch Database Preview

DEGARELIX ACETATE - Generic Drug Details

» See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for degarelix acetate and what is the scope of freedom to operate?

Degarelix acetate is the generic ingredient in one branded drug marketed by Ferring and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Degarelix acetate has one hundred and thirty-six patent family members in thirty-six countries.

One supplier is listed for this compound.

Recent Clinical Trials for DEGARELIX ACETATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Wonju Severance Christian HospitalPhase 4
Eulji University HospitalPhase 4
Xiao X. WeiPhase 2

See all DEGARELIX ACETATE clinical trials

Recent Litigation for DEGARELIX ACETATE

Identify potential future generic entrants

District Court Litigation
Case NameDate
Salk Institute for Biological Studies v. Ferring Pharmaceuticals, Inc2010-12-22

See all DEGARELIX ACETATE litigation

Synonyms for DEGARELIX ACETATE
214766-78-6
766D786
934016-19-0
934246-14-7
A12840
Ac-D-Nal-[D-(pCl)Phe]-D-Pal-Ser-[Aph(DHor)]-D-[Aph(Cbm)]-Leu-ILys-Pro-DAla-NH2
Acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
ASP-3550
ASP3550
BDBM50102450
CHEBI:135961
CHEMBL2028987
CHEMBL415606
CS-5350
D-Alaninamide, N-acetyl-3-(naphtalen-2-yl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-4-((((4S)-2,6-dioxohexahydropyrimidin-4-yl)carbonyl)amino)-L-phenylalanyl-4-(carbamoylamino)-D-phenylalanyl-L-leuc
D08635
D08901
D09400
DB06699
Degarelix
Degarelix (acetate) pound>>FE 200486
Degarelix (INN/USAN)
Degarelix [USAN:INN:BAN]
Degarelix acetate (JAN)
Degarelix acetate (USAN)
Degarelix acetate hydrate
Degarelix monoacetate
EXT215F4ZU
FE 200486
FE-200486
FE-200486 (free base)
FE200486
FE200486 (AS ACETATE SALT)
Firmagon
Firmagon (TN)
Gonax
GTPL5585
HSDB 7817
HY-16168A
N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-4-[[[(4S)-hexahydro-2,6-dioxo-4-pyrimidinyl]carbonyl]amino]-L-phenylalanyl-4-[(aminocarbonyl)amino]-D-phenylalanyl-L-leucyl-N6-(1-
N-Acetyl-3-(naphtalen-2-yl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-4-((((4S)-2,6-dioxohexahydropyrimidin-4-yl)carbonyl)amino)-L-phenylalanyl-4-(carbamoylamino)-D-phenylalanyl-L-leucyl-N(sup 6)-(1-
Q1182795
Q27277419
QC-10170
SCHEMBL1397034
SCHEMBL21050504
SX0XJI3A11
Uglypeptide1
UNII-EXT215F4ZU
UNII-SX0XJI3A11
Z-3147
Paragraph IV (Patent) Challenges for DEGARELIX ACETATE
Tradename Dosage Ingredient NDA Submissiondate
FIRMAGON POWDER;SUBCUTANEOUS degarelix acetate 022201 2019-12-20

US Patents and Regulatory Information for DEGARELIX ACETATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ferring FIRMAGON degarelix acetate POWDER;SUBCUTANEOUS 022201-002 Dec 24, 2008 RX Yes Yes   Start Trial   Start Trial   Start Trial
Ferring FIRMAGON degarelix acetate POWDER;SUBCUTANEOUS 022201-001 Dec 24, 2008 RX Yes No   Start Trial   Start Trial   Start Trial
Ferring FIRMAGON degarelix acetate POWDER;SUBCUTANEOUS 022201-001 Dec 24, 2008 RX Yes No   Start Trial   Start Trial   Start Trial
Ferring FIRMAGON degarelix acetate POWDER;SUBCUTANEOUS 022201-002 Dec 24, 2008 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Ferring FIRMAGON degarelix acetate POWDER;SUBCUTANEOUS 022201-001 Dec 24, 2008 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for DEGARELIX ACETATE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1003774 PA2009005,C1003774 Lithuania   Start Trial PRODUCT NAME: DEGARELIXUM ACETAT; REGISTRATION NO/DATE: EU/1/08/504/001, 2009 02 17 EU/1/08/504/002 20090217
1003774 SPC020/2009 Ireland   Start Trial SPC020/2009: 20091119, EXPIRES: 20230412
1003774 91585 Luxembourg   Start Trial PRODUCT NAME: DEGARELIX, EVENTUELLEMENT UN SEL PHARMACEUTIQUEMENT ACCEPTABE, TEL QUE L'ACETATE (FIRMAGON); REG. DATE: 20090217
1003774 C01003774/01 Switzerland   Start Trial PRODUCT NAME: DEGARELIX; REGISTRATION NUMBER/DATE: SWISSMEDIC 59455 12.02.2010
1003774 CA 2009 00022 Denmark   Start Trial
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
AstraZeneca
Medtronic
McKinsey
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.